Erasca Director Granted 120,000 Stock Options at $1.45 – Form 4
Form 4 overview: On 06/24/2025, Erasca, Inc. (ticker ERAS) granted Director Pratik S. Multani a stock option to purchase 120,000 shares of common stock at an exercise price of $1.45 per share.
Rhea-AI Filing Summary
Form 4 overview: On 06/24/2025, Erasca, Inc. (ticker ERAS) granted Director Pratik S. Multani a stock option to purchase 120,000 shares of common stock at an exercise price of $1.45 per share.
Key terms:
- Vesting: 100% of the option vests on 06/24/2026, contingent on continued service.
- Expiration: 06/23/2035, providing a 10-year exercise window after vesting.
- Ownership form: Direct.
No other acquisitions, dispositions, or non-derivative holdings were reported. The filing reflects a routine equity incentive intended to align the director’s interests with shareholders rather than an open-market purchase or sale. The disclosure contains no financial performance data or forward-looking statements.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine director option grant; minimal immediate valuation impact.
The single grant of 120,000 options at $1.45 is a standard equity incentive. It does not involve cash outlay by the company today, and dilution is immaterial without exercise. No buying or selling of existing shares occurred, so the filing offers little insight into management’s outlook or near-term trading sentiment. Absent company share count data, the award appears modest and typical for small-cap biotech boards. Overall, I view the filing as a normal course administrative disclosure with negligible effect on valuation.
TL;DR: Standard incentive; aligns director interests, no red flags detected.
The option vests after one year of continued service, consistent with common best-practice designs that encourage retention. A 10-year term is conventional. Because the option is granted at-the-money, it links upside to shareholder returns without creating immediate accounting expense beyond fair-value recognition. No indications of 10b5-1 plan usage or accelerated vesting clauses are noted. Governance implications are neutral: transparent disclosure, appropriate signing authority, and no indication of unusual preferential treatment.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) | 120,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. 100% of the options to purchase shares vest on June 24, 2026, subject to the Reporting Person's continuous service to the Issuer on such vesting date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who filed the Form 4 for Erasca (ERAS)?
What is the exercise price of the option granted on 06/24/2025?
When do the options vest and expire?
Is this Form 4 indicative of insider buying or selling in the open market?
AI-generated analysis. How Rhea-AI works. Not financial advice.